Clinical effects of proton pump inhibitors: Focus on pharmacogenetics, kinetics and dynamics
This thesis describes the clinical effects of proton pump inhibitors, with focus on pharmacogenetics, kinetics and dynamics. The aims were to investigate the occurence of Rebound Acid Hypersecretion and to investigate the speed of onset, the duration of effect and the difference in acid-inhibition between esomeprazole, rabeprazole and pantoprazole. Furthermore the prevalence of CYP2C19 polymorphism was studied in a Caucasian population. The influence of CYP2C19 polymorphism on acid-inhibition and pharmacokinetics of proton pump inhibitors in Caucasians was also studied.
|Keywords||CYP2C19, PPIs, esomeprazole, intragastric pH, lansoprazole, omeprazole, pantoprazole, pharmacodynamics, pharmacogenetics, pharmacokinetics, proton pump inhibitors, rabeprazol, rebound acid hypersecretion|
|Promotor||E.J. Kuipers (Ernst)|
|Publisher||Erasmus University Rotterdam , Haga Ziekenhuis, Den Haag|
|Sponsor||Apotheek Haagse Ziekenhuizen, AstraZeneca B.V., Bayer Schering Pharma, Fresenius-Kabi B.V., HagaZiekenhuis, Inge Voesten-Appel stichting, Nederlandse Vereniging voor Gastroenterologie|
Hunfeld, N.G.M.. (2010, September 24). Clinical effects of proton pump inhibitors: Focus on pharmacogenetics, kinetics and dynamics. Haga Ziekenhuis, Den Haag. Retrieved from http://hdl.handle.net/1765/21086